Compound Evidence File
#EC-2026-0080
T3 (Liothyronine)
Filed under Oral Tablets. The bureau holds 155 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 24 Nov 2025 | 23 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Mar 2026 | 11 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 10.0 | 10.0 | 20 Mar 2026 | 22 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Nov 2025 | 2 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 22 May 2026 | 9 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 10.0 | 10.0 | 7 May 2026 | 5 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 10 Feb 2026 | 20 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 13 Jan 2026 | 8 Mar 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Jan 2026 | 23 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Apr 2026 | 10 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Dec 2025 | 23 Mar 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 20 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 26 Jun 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 9.1 | 8.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.9 | 7.9 | 9.3 | 21 May 2026 | 21 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 8.9 | 8.9 | 8.9 | 14 Jan 2025 | 14 Jan 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.8 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.6 | 7.6 | 9.7 | 24 May 2026 | 24 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 8.5 | 8.5 | 8.5 | 16 Mar 2025 | 16 Mar 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.2 | 6.0 | 10.0 | 25 May 2026 | 25 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 8.2 | 7.6 | 8.9 | 20 Jun 2025 | 20 May 2026 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 8.2 | 8.2 | 8.2 | 13 Feb 2025 | 13 Feb 2025 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 8.2 | 8.2 | 8.2 | 8 Jul 2025 | 8 Jul 2025 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 8.0 | 8.0 | 8.0 | 11 Jun 2025 | 11 Jun 2025 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 7.8 | 6.8 | 8.8 | 3 Jun 2025 | 19 Jan 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 6 | 7.7 | 6.7 | 9.5 | 28 Mar 2025 | 21 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 7.7 | 7.7 | 7.7 | 27 Feb 2025 | 27 Feb 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 7.5 | 7.5 | 7.5 | 9 Jun 2025 | 9 Jun 2025 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 7.3 | 7.3 | 7.3 | 6 May 2025 | 6 May 2025 |
| Royal PeptidesCASE #VI-2026-0264 | X | 1 | 7.0 | 7.0 | 7.0 | 25 Apr 2025 | 25 Apr 2025 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 2 | 6.9 | 6.6 | 7.2 | 6 May 2025 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 1 | 6.9 | 6.9 | 6.9 | 14 Jan 2025 | 14 Jan 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | E | 2 | 6.8 | 6.2 | 7.5 | 13 Feb 2025 | 17 May 2026 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 6.7 | 6.7 | 6.7 | 16 Mar 2025 | 16 Mar 2025 |
| NexaphCASE #VI-2026-0944 | X | 15 | 6.6 | 3.7 | 8.8 | 13 Jun 2025 | 25 May 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 3 | 6.5 | 5.9 | 7.5 | 20 Jun 2025 | 23 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 6.5 | 6.5 | 6.5 | 13 Feb 2025 | 13 Feb 2025 |
| BeiBangAnCASE #VI-2026-0899 | X | 2 | 6.2 | 5.7 | 6.6 | 14 Jan 2025 | 24 May 2026 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 6.2 | 6.2 | 6.2 | 21 May 2025 | 21 May 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 6.1 | 6.1 | 6.1 | 20 Jun 2025 | 20 Jun 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 6.1 | 6.1 | 6.1 | 2 Jul 2025 | 2 Jul 2025 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 6.1 | 6.1 | 6.1 | 17 Dec 2024 | 17 Dec 2024 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 6.0 | 6.0 | 6.0 | 28 Mar 2025 | 28 Mar 2025 |
| Loti LabsCASE #VI-2026-0171 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.6 | 5.6 | 5.6 | 3 Jul 2025 | 3 Jul 2025 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 5.6 | 5.6 | 5.6 | 7 May 2025 | 7 May 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 5.5 | 5.5 | 5.5 | 6 May 2025 | 6 May 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 3 | 5.4 | 4.2 | 6.0 | 17 Dec 2024 | 20 May 2026 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 5.4 | 5.4 | 5.4 | 2 Jul 2025 | 2 Jul 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 5.2 | 5.2 | 5.2 | 17 Dec 2024 | 17 Dec 2024 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 4.7 | 4.7 | 4.7 | 24 Apr 2025 | 24 Apr 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 4.3 | 4.3 | 4.3 | 2 Jul 2025 | 2 Jul 2025 |
| TydesCASE #VI-2026-0493 | X | 4 | 4.2 | 2.8 | 5.9 | 17 Dec 2024 | 17 May 2026 |
| Amino AmigosCASE #VI-2026-0061 | X | 2 | 2.4 | 1.9 | 2.9 | 7 May 2025 | 17 May 2026 |
| Peptide GurusCASE #VI-2026-0854 | X | 4 | 1.9 | 0.8 | 3.3 | 9 Jun 2025 | 21 May 2026 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 1.0 | 1.0 | 1.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for T3 (Liothyronine) alone.